Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Disc Medicine (NASDAQ:IRON) and maintained a price target of $85.
October 15, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Disc Medicine, maintaining a price target of $85, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst suggests positive sentiment and potential for stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100